AML
New Treatment OK’d for Newly Diagnosed IDH1-Mutant AML
The FDA approved the combination of ivosidenib (Tibsovo, Servier) plus azacitidine for adults aged 75 years and ...
MAY 27, 2022
Onureg, Oral Formulation of Azacitidine, Approved for AML
The FDA granted approval to azacitidine tablets (Onureg, Celgene) for treatment of patients with acute myeloid ...
SEPTEMBER 4, 2020
FDA Expands Use of Mylotarg to Infants at Least 1 Month Old
The FDA extended the indication for gemtuzumab ozogamicin (Mylotarg, Wyeth) to treat newly diagnosed CD33-positive ...
JUNE 19, 2020
FDA Approves Vyxeos for 2 Types of AML
The FDA approved Vyxeos, Jazz Pharmaceuticals)to treat adults with two types of acute myeloid leukemia (AML): newly ...
AUGUST 4, 2017
FDA Approves Idhifa and RealTime IDH2 Assay for Relapsed or Refractory AML
Celgene's Idhifa was approved to treat adult patients with relapsed or refractory AML who have a specific genetic ...
AUGUST 2, 2017
Vyxeos Increases Survival in High-Risk AML
Experimental treatment reduced the risk for death by 31% for older patients with secondary acute myeloid leukemia.
MARCH 28, 2016
